ABC | Volume 113, Nº3, Setembro 2019

Artigo de Revisão Calderaro et al. Hipertensão pulmonar na prática do cardiologista Arq Bras Cardiol. 2019; 113(3):419-428 11. GalieN, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. 12. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48(12):2546-52. 13. Gavilanes F, Alves Jr JL, Fernandes C, Prada LF, JardimCV, Morinaga LT, et al. Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension. J Bras Pneumol. 2014;40(6):609-16. 14. Souza R, Fernandes CJ, Jardim CV. Other causes of PAH (schistosomiasis, porto-pulmonary hypertension and hemolysis-associated pulmonary hypertension). Semin Respir Crit Care Med. 2009;30(4):448-57. 15. Alves JL, Jr., Gavilanes F, Jardim C, Fernandes CJ, Morinaga LT, Dias B, et al. Pulmonary arterial hypertension in the southern hemisphere: results froma registry of incident Brazilian cases. Chest. 2015;147(2):495-501. 16. Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Morinaga LK, Souza R. Schistosomiasis and pulmonary hypertension. Expert Rev Respir Med. 2011;5(5):675-81. 17. Julio Cesar Fernandes C, Piloto B, Castro M, Gavilanes Oleas F, Leonidas Alves J, Jr., Felipe Lopes Prada L, et al. Survival of schistosomiasis-associated pulmonary arterial hypertension in themodernmanagement era. Eur Respir J. 2018; 51(6). 18. Gavilanes F, Fernandes CJ, Souza R. Pulmonary arterial hypertension in schistosomiasis. Curr Opin PulmMed. 2016;22(5):408-14. 19. Alves JL, Jr., Oleas FG, Souza R. Pulmonary Hypertension: Definition, Classification,andDiagnosis.SeminRespirCritCareMed.2017;38(5):561-70. 20. Palazzini M, Dardi F, Manes A, Bacchi Reggiani ML, Gotti E, Rinaldi A, et al. Pulmonaryhypertensiondueto leftheartdisease:analysisofsurvivalaccording to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail. 2018;20(2):248-55. 21. Vachiéry J-L, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019;53(1). 22. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306-22. 23. Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D92-9. 24. Hoette S, Jardim C, Souza R. Diagnosis and treatment of pulmonary hypertension: an update. J Bras Pneumol. 2010;36(6):795-811. 25. Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC, Jr. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest. 2002;122(2):524-7. 26. Hoette S, Figueiredo C, Dias B, Alves-Jr JL, Gavilanes F, Prada LF, et al. Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. BMC PulmMed. 2015;15:118. 27. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. Ventilation-perfusion scintigraphy is more sensitive thanmultidetector CTPA indetecting chronicthromboembolicpulmonarydisease asatreatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680-4. 28. Masy M, Giordano J, Petyt G, Hossein-Foucher C, Duhamel A, Kyheng M, et al. Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol. 2018; 28(12):5100-5110. 29. Rudski LG, LaiWW, Afilalo J, Hua L, HandschumacherMD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713 30. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Suppl):D51-9. 31. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D73-81. 32. Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2). 33. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. 34. de Carvalho AC, Hovnanian AL, Fernandes CJ, Lapa M, Jardim C, Souza R. Tadalafil as treatment for idiopathic pulmonary arterial hypertension. Arq Bras Cardiol. 2006;87(5):e195-7. 35. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301. 36. Jardim C, Fernandes CJ, Souza R. Goal-oriented treatment of pulmonary arterial hypertension. Curr Opin PulmMed. 2014;20(5):409-13. 37. Dos Santos Fernandes CJC, Humbert M, Souza R. Challenging the concept of adding more drugs in pulmonary arterial hypertension. Eur Respir J. 2017;50(3). 38. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). AmHeart J. 1997;134(1):44-54. 39. Sueta CA, Gheorghiade M, Adams KF, Jr., Bourge RC, Murali S, Uretsky BF, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol. 1995;75(3):34A-43A. 40. Sutsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98(21):2262-8. 41. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85(2-3):195-7. 42. Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, et al. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. JACC Heart Fail. 2017;5(5):317-26. 43. Luscher TF, Enseleit F, Pacher R, Mitrovic V, SchulzeMR,Willenbrock R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106(21):2666-72. 44. AnandI,McMurrayJ,CohnJN,KonstamMA,NotterT,QuitzauK,etal.Long-term effectsofdarusentanon left-ventricularremodellingandclinicaloutcomesinthe EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind,placebo-controlledtrial.Lancet.2004;364(9431):347-54. 427